{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T19:25:40Z","timestamp":1758050740110,"version":"3.44.0"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cellular Immunology"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1016\/j.cellimm.2018.08.016","type":"journal-article","created":{"date-parts":[[2018,8,28]],"date-time":"2018-08-28T17:09:25Z","timestamp":1535476165000},"page":"38-41","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Anti-drug antibodies to LMB-100 are enhanced by mAbs targeting OX40 and CTLA4 but not by mAbs targeting PD1 or PDL-1"],"prefix":"10.1016","volume":"334","author":[{"given":"Ronit","family":"Mazor","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emily","family":"King","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ira","family":"Pastan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cellimm.2018.08.016_b0005","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1097\/01.pai.00000141545.36485.d6","article-title":"Localization of mesothelin in epithelial ovarian cancer","volume":"13","author":"Hassan","year":"2005","journal-title":"Appl. Immunohistochem. Mol. Morphol."},{"key":"10.1016\/j.cellimm.2018.08.016_b0010","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1158\/1535-7163.MCT-14-0089-T","article-title":"In vitro and in vivo activity of the low-immunogenic antimesothelin immunotoxin RG7787 in pancreatic cancer","volume":"13","author":"Hollevoet","year":"2014","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.cellimm.2018.08.016_b0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","article-title":"Oncology meets immunology: the cancer-immunity cycle","volume":"39","author":"Chen","year":"2013","journal-title":"Immunity"},{"key":"10.1016\/j.cellimm.2018.08.016_b0020","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1001\/jamaoncol.2015.4368","article-title":"Ipilimumab therapy in patients with advanced melanoma and preexisting autoimmune disorders","volume":"2","author":"Johnson","year":"2016","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.cellimm.2018.08.016_b0025","doi-asserted-by":"crossref","first-page":"233","DOI":"10.4161\/mabs.2.3.11782","article-title":"Safety and immunotoxicity assessment of immunomodulatory monoclonal antibodies","volume":"2","author":"Brennan","year":"2010","journal-title":"mAbs"},{"key":"10.1016\/j.cellimm.2018.08.016_b0030","doi-asserted-by":"crossref","DOI":"10.1177\/1758835918762094","article-title":"Combination of immunotherapy with chemotherapy and radiotherapy in lung cancer: is this the beginning of the end for cancer?","volume":"10","author":"Lazzari","year":"2018","journal-title":"Ther. Adv. Med. Oncol."},{"key":"10.1016\/j.cellimm.2018.08.016_b0035","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1158\/2326-6066.CIR-15-0064","article-title":"The interplay of immunotherapy and chemotherapy: harnessing potential synergies","volume":"3","author":"Emens","year":"2015","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.cellimm.2018.08.016_b0040","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3006941","article-title":"Major cancer regressions in mesothelioma after treatment with an anti-mesothelin immunotoxin and immune suppression","volume":"5","author":"Hassan","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.cellimm.2018.08.016_b0045","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1111\/imm.12099","article-title":"Beyond DNA repair, the immunological role of PARP-1 and its siblings","volume":"139","author":"Rosado","year":"2013","journal-title":"Immunology"},{"key":"10.1016\/j.cellimm.2018.08.016_b0050","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1158\/2326-6066.CIR-16-0330","article-title":"Combining local immunotoxins targeting mesothelin with CTLA-4 blockade synergistically eradicates murine cancer by promoting anti-cancer immunity","volume":"6","author":"Leshem","year":"2017","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.cellimm.2018.08.016_b0055","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/j.molonc.2016.07.003","article-title":"Characterization of a re-engineered, mesothelin-targeted Pseudomonas exotoxin fusion protein for lung cancer therapy","volume":"10","author":"Bauss","year":"2016","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.cellimm.2018.08.016_b0060","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1038\/cmi.2015.91","article-title":"Elimination of murine and human T-cell epitopes in recombinant immunotoxin eliminates neutralizing and anti-drug antibodies in vivo","volume":"14","author":"Mazor","year":"2017","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.cellimm.2018.08.016_b0065","doi-asserted-by":"crossref","first-page":"11782","DOI":"10.1073\/pnas.1209292109","article-title":"Recombinant immunotoxin engineered for low immunogenicity and antigenicity by identifying and silencing human B-cell epitopes","volume":"109","author":"Liu","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.cellimm.2018.08.016_b0070","doi-asserted-by":"crossref","first-page":"E733","DOI":"10.1073\/pnas.1717063115","article-title":"Tolerogenic nanoparticles restore the antitumor activity of recombinant immunotoxins by mitigating immunogenicity","volume":"115","author":"Mazor","year":"2018","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.cellimm.2018.08.016_b0075","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.nbt.2009.03.012","article-title":"How to systematically evaluate immunogenicity of therapeutic proteins-regulatory considerations","volume":"25","author":"Jahn","year":"2009","journal-title":"N. Biotechnol."},{"key":"10.1016\/j.cellimm.2018.08.016_b0080","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1424674","article-title":"Development of anti-drug antibodies is associated with shortened survival in patients with metastatic melanoma treated with ipilimumab","volume":"7","author":"Kverneland","year":"2018","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.cellimm.2018.08.016_b0085","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1158\/1078-0432.CCR-14-1339","article-title":"Curing mice with large tumors by locally delivering combinations of immunomodulatory antibodies","volume":"21","author":"Dai","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.cellimm.2018.08.016_b0090","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1158\/2326-6066.CIR-13-0198","article-title":"Microtubule-depolymerizing agents used in antibody-drug conjugates induce antitumor immunity by stimulation of dendritic cells","volume":"2","author":"Muller","year":"2014","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.cellimm.2018.08.016_b0095","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1038\/nm.4200","article-title":"Eradication of large established tumors in mice by combination immunotherapy that engages innate and adaptive immune responses","volume":"22","author":"Moynihan","year":"2016","journal-title":"Nat. Med."},{"key":"10.1016\/j.cellimm.2018.08.016_b0100","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/nature14292","article-title":"Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer","volume":"520","author":"Twyman-Saint Victor","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.cellimm.2018.08.016_b0105","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.chom.2015.03.007","article-title":"PD-1 Co-inhibitory and OX40 Co-stimulatory crosstalk regulates helper T cell differentiation and anti-plasmodium humoral immunity","volume":"17","author":"Zander","year":"2015","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.cellimm.2018.08.016_b0110","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1172\/JCI67313","article-title":"Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice","volume":"124","author":"Deng","year":"2014","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.cellimm.2018.08.016_b0115","article-title":"PD-1 blockade and OX40 triggering synergistically protects against tumor growth in a murine model of ovarian cancer","volume":"9","author":"Guo","year":"2014","journal-title":"PLoS One"}],"container-title":["Cellular Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0008874918303770?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0008874918303770?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T22:57:39Z","timestamp":1757804259000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0008874918303770"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":23,"alternative-id":["S0008874918303770"],"URL":"https:\/\/doi.org\/10.1016\/j.cellimm.2018.08.016","relation":{},"ISSN":["0008-8749"],"issn-type":[{"type":"print","value":"0008-8749"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anti-drug antibodies to LMB-100 are enhanced by mAbs targeting OX40 and CTLA4 but not by mAbs targeting PD1 or PDL-1","name":"articletitle","label":"Article Title"},{"value":"Cellular Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cellimm.2018.08.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}